Research Analysts Set Expectations for ABCL Q2 Earnings

AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Equities researchers at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for AbCellera Biologics in a report released on Monday, July 7th. Leerink Partnrs analyst F. Khurshid anticipates that the company will earn ($0.16) per share for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for AbCellera Biologics' current full-year earnings is ($0.59) per share. Leerink Partnrs also issued estimates for AbCellera Biologics' Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.64) EPS and FY2026 earnings at ($0.28) EPS.

Other research analysts have also recently issued research reports about the company. Leerink Partners started coverage on AbCellera Biologics in a research report on Monday. They issued an "outperform" rating and a $5.00 price target for the company. KeyCorp boosted their price target on AbCellera Biologics from $4.00 to $5.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. Finally, Truist Financial lowered their price objective on AbCellera Biologics from $28.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, May 16th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, AbCellera Biologics has an average rating of "Buy" and a consensus price target of $7.50.

AbCellera Biologics Trading Down 3.5%

Shares of ABCL opened at $3.89 on Wednesday. The firm has a market capitalization of $1.16 billion, a P/E ratio of -6.95 and a beta of 0.62. The firm's 50-day moving average is $2.72 and its two-hundred day moving average is $2.74. AbCellera Biologics has a twelve month low of $1.89 and a twelve month high of $4.12.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.02. The business had revenue of $4.24 million during the quarter, compared to the consensus estimate of $7.12 million. AbCellera Biologics had a negative return on equity of 15.98% and a negative net margin of 737.56%.

Institutional Trading of AbCellera Biologics

Several hedge funds have recently bought and sold shares of the company. DKM Wealth Management Inc. acquired a new stake in shares of AbCellera Biologics in the fourth quarter valued at approximately $29,000. Stratos Wealth Advisors LLC bought a new position in AbCellera Biologics in the 1st quarter worth approximately $27,000. Janney Montgomery Scott LLC acquired a new stake in AbCellera Biologics in the 1st quarter valued at approximately $29,000. Balyasny Asset Management L.P. bought a new stake in AbCellera Biologics during the 4th quarter valued at $40,000. Finally, Mariner LLC bought a new stake in AbCellera Biologics during the 4th quarter valued at $42,000. 61.42% of the stock is currently owned by institutional investors.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.